HK1039477A1 - 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors - Google Patents

2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors

Info

Publication number
HK1039477A1
HK1039477A1 HK01108745A HK01108745A HK1039477A1 HK 1039477 A1 HK1039477 A1 HK 1039477A1 HK 01108745 A HK01108745 A HK 01108745A HK 01108745 A HK01108745 A HK 01108745A HK 1039477 A1 HK1039477 A1 HK 1039477A1
Authority
HK
Hong Kong
Prior art keywords
rxr
retinoid
receptors
acid derivatives
selective activity
Prior art date
Application number
HK01108745A
Other languages
English (en)
Inventor
Vidyasagar Vuligonda
Kwok Yin Tsang
Jayasree Vasudevan
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1039477A1 publication Critical patent/HK1039477A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01108745A 1998-10-01 2002-02-25 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors HK1039477A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,950 US6147224A (en) 1998-10-01 1998-10-01 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
PCT/US1999/021712 WO2000020370A1 (en) 1998-10-01 1999-09-20 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors

Publications (1)

Publication Number Publication Date
HK1039477A1 true HK1039477A1 (en) 2002-04-26

Family

ID=22596791

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108745A HK1039477A1 (en) 1998-10-01 2002-02-25 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors

Country Status (17)

Country Link
US (1) US6147224A (pt)
EP (2) EP1117628B1 (pt)
JP (1) JP2002526516A (pt)
KR (2) KR20010075457A (pt)
CN (1) CN1328538A (pt)
AR (1) AR020691A1 (pt)
AT (1) ATE254593T1 (pt)
AU (1) AU757932B2 (pt)
BR (1) BR9914256A (pt)
CA (1) CA2346034A1 (pt)
DE (1) DE69912973T2 (pt)
ES (1) ES2207339T3 (pt)
HK (1) HK1039477A1 (pt)
NZ (1) NZ510528A (pt)
TW (1) TW580494B (pt)
WO (1) WO2000020370A1 (pt)
ZA (1) ZA200102635B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016133A2 (en) 1999-08-27 2001-03-08 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
HUP0202814A3 (en) 1999-08-27 2003-11-28 Ligand Pharmaceuticals Inc San Androgen receptor modulator compounds and methods for their preparation and pharmaceutical compositions containing them and their use
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CO5200852A1 (es) * 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
EP1408946A4 (en) * 2001-03-27 2004-06-09 Circagen Pharmaceutical HISTONE DEACETYLASE INHIBITORS
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
AU2003243272A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
SI1937244T1 (sl) 2005-09-30 2018-12-31 Io Therapeutics, Llc Zdravljenje raka s specifičnimi RXR agonisti
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
CA2858882C (en) 2011-12-13 2021-02-02 Trustees Of Dartmouth College Autoimmune disorder treatment using rxr agonists
KR102225715B1 (ko) 2013-07-09 2021-03-09 토소가부시키가이샤 아다만틸기를 가진 환상 아진 화합물, 제조 방법, 및 상기 화합물을 구성 성분으로서 함유하는 유기 전계발광소자
NZ741393A (en) 2015-10-31 2018-11-30 Io Therapeutics Inc Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
PL3426303T3 (pl) 2016-03-10 2022-10-03 Io Therapeutics, Inc. Leczenie zaburzeń mięśniowych za pomocą kombinacji agonistów rxr i hormonów tarczycy
US10946001B2 (en) * 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10590059B2 (en) * 2017-11-17 2020-03-17 Io Therapeutics, Inc. Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023108015A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826760D0 (en) * 1988-11-16 1988-12-21 Wellcome Found Pesticides
ES2066750T3 (es) * 1991-12-18 1998-07-01 Salk Inst For Biological Studi Metodo para la modulacion de procesos mediatizados por receptores de retinoides y compuestos de utilidad en dicho metodo.
DE10199033I2 (de) * 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
ES2129115T3 (es) * 1993-01-11 1999-06-01 Ligand Pharm Inc Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
CA2196197C (en) * 1994-08-10 2007-04-17 Michael Klaus Retinoic acid x-receptor ligands
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
ES2190479T3 (es) * 1995-10-06 2003-08-01 Ligand Pharm Inc Moduladores de rxr selectivos a dimeros y metodos para su uso.
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
WO2000053562A1 (en) * 1999-03-08 2000-09-14 Basilea Pharmaceutica Ag Retinoid antagonists and use thereof

Also Published As

Publication number Publication date
KR20060118367A (ko) 2006-11-23
BR9914256A (pt) 2001-07-03
EP1117628A1 (en) 2001-07-25
TW580494B (en) 2004-03-21
EP1117628B1 (en) 2003-11-19
CN1328538A (zh) 2001-12-26
AR020691A1 (es) 2002-05-22
ZA200102635B (en) 2002-10-18
KR20010075457A (ko) 2001-08-09
WO2000020370A1 (en) 2000-04-13
AU757932B2 (en) 2003-03-13
US6147224A (en) 2000-11-14
ES2207339T3 (es) 2004-05-16
EP1388534A2 (en) 2004-02-11
DE69912973D1 (de) 2003-12-24
ATE254593T1 (de) 2003-12-15
JP2002526516A (ja) 2002-08-20
NZ510528A (en) 2003-04-29
CA2346034A1 (en) 2000-04-13
AU6051399A (en) 2000-04-26
EP1388534A3 (en) 2004-02-25
DE69912973T2 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
HK1039477A1 (en) 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
IL139636A0 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
ZA962157B (en) Percarboxylic acid rinse method.
HUP0001322A3 (en) Sulphinic acid derivatives, method for producing them, and their use
PT925298E (pt) Derivados 6,6-hetero-biciclicos substituidos
IL128188A0 (en) ,7-bicyclic derivatives substituted pyrido-or pyrimido-containing 6,6-or 6
NL1012963A1 (nl) 2-Amino-bicyclo (3.1.0)hexaan-2,6 dicarbonzuur derivaten en een werkwijze voor de bereiding ervan.
EP0951283A4 (en) NEW METABOLITE OF ARACHIDONIC ACID: 4 PM
HUP0103659A2 (en) Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
BR9502431A (pt) Método para minimizar o intervalo de tempo para um receptor operando durante um modo de recepçao descontinua
HU9502684D0 (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkane-carboxylic acid derivatives
AU2001243630A1 (en) 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr)receptors
NZ239161A (en) Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0845457A4 (en) 2,2-DIDEUTERO-5-AMINOLEVULINIC ACID
AU2003230720A1 (en) Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentaidenoic acid derivatives having selective activity for retinoid x (rxr) receptors
GB2329656B (en) A sinker bar for cable-operated well apparatus
AU2002331876A1 (en) Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
HU9203078D0 (en) Method for regionally selective production of 1,5-diamide-pyrazole derivatives
ZA957615B (en) Process for R(+)1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenyl-3-cyclohexen-1-yl) methyl]pyridine a central nervous system agent
AU6864100A (en) Method for producing 2,6-dimethylnaphthalene
ZA965713B (en) 5-pyrazolylbenzoic acid derivatives.
HUP9801312A3 (en) Process for producing 3,3-dimethyl-butyric acid
HU9802526D0 (en) Improved process for producing 4-cyano-4-(substituted-indazole)-cyclohexane-carboxylic acid derivatives
ZA969205B (en) Pyridyle acetic acid derivatives, process and intermediates for their preparation and agents containing them.
AU9556298A (en) Trienoic retinoid compounds as retinoic acid receptor antagonists

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090920